Abstract

The present invention relates to a composite material comprising a porous solid support and at least one malonamide non-covalently bonded to the surface of this porous solid support. The present invention also relates to a process for preparing such a material and also to the use thereof for extracting and recovering palladium from an acid leaching solution containing same.

IPC Classes  ?

• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/32 - Impregnating or coating
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C22B 11/00 - Obtaining noble metals

Abstract

The present invention relates to isolated single domain antibodies having specificity for deNEDDylating enzyme NEDP1. It concerns in particular to a kit for inhibiting the deNEDDylating enzyme NEDP1, more particularly for the prevention and/or treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis and/or Frontotemporal Degeneration, said kit comprising at least one isolated single domain antibody specific for the deNEDDylating enzyme NEDP1. It further relates to said isolated single domain antibodies for use as inhibitors of the deNEDDylating enzyme NEDP1, in particular for the prevention and/or treatment of neurodegenerative diseases such as ALS/FTD.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A method of treating an inflammatory disease selected from the group of atherosclerosis, ankylosing spondylitis, and Sjogren syndrome. The method includes administering a quinoline derivative to a patient in need thereof. The quinoline derivative is a compound of formula (I) A method of treating an inflammatory disease selected from the group of atherosclerosis, ankylosing spondylitis, and Sjogren syndrome. The method includes administering a quinoline derivative to a patient in need thereof. The quinoline derivative is a compound of formula (I) A method of treating an inflammatory disease selected from the group of atherosclerosis, ankylosing spondylitis, and Sjogren syndrome. The method includes administering a quinoline derivative to a patient in need thereof. The quinoline derivative is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 215/38 - Nitrogen atoms
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to a process for synthesis of a benzophenone or a benzophenone derivative which uses a metal base with a solvent selected from linear or cyclic carboxamides for activating a compound of formula (II) and allowing it to be coupled with a compound of formula (I) so as to give said benzophenone or said benzophenone derivative.

IPC Classes  ?

• C07C 45/45 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by condensation
• C07D 213/50 - Ketonic radicals
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07C 45/46 - Friedel-Crafts reactions
• C07D 317/54 - Radicals substituted by oxygen atoms

Abstract

122 are as defined herein, or a pharmaceutically acceptable salt or solvate thereof, where said compounds of formula (I) are 3,5-dialkoxypyridine (DARQ) analogues of bedaquiline (BDQ) and may be used in the treatment of a nontuberculous mycobacterial (NTM) infection.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 31/04 - Antibacterial agents
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a multilayer material, comprising a solid substrate coated at least partially with a textured α-quartz buffer layer, the crystallographic direction of the α-quartz being parallel to the crystallographic direction of the silicon; and on said α-quartz buffer layer, a layer of one-dimensional epitaxial ZnO microcrystals (or epitaxial ZnO microwires), said microcrystals being self-assembled. The present invention also relates to a method for producing such a multilayer material, as well as to the industrial use thereof in various technical fields.

IPC Classes  ?

• C30B 29/62 - Whiskers or needles
• C30B 5/00 - Single-crystal growth from gels
• C30B 7/00 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
• C30B 7/10 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by application of pressure, e.g. hydrothermal processes
• C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
• C30B 29/16 - Oxides
• H03H 9/17 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator
• H03H 9/19 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator consisting of quartz

Abstract

A pattern learning and recognition device including a training unit adapted to train an oscillatory neural network, the training unit being a part of a processor, an oscillatory neural network unit, the oscillatory neural network unit implementing a trained oscillatory neural network being adapted to output a pattern when an image is inputted, the oscillatory neural network unit being a part of a programmable architecture, and a controlling unit adapted to control the oscillatory neural network unit and the training unit, the controlling unit being another part of the programmable architecture, the processor and the programmable architecture forming a system-on-chip.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting

Abstract

RNA interferent (RNAi) molecules that inhibit a PMP22 protein expression and/or activity by targeting exon 5 of a nucleic acid sequence encoding the PMP22 protein, and the prevention and treatment of the Charcot-Marie-Tooth type 1A or 1E diseases in which an adeno-associated virus (AAV) vector including an RNAi molecule is administered.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C12N 15/86 - Viral vectors

Abstract

The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 35/00 - Antineoplastic agents
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 471/04 - Ortho-condensed systems
• C07F 5/02 - Boron compounds

Abstract

There is an interest to develop anti-ROBO4 antibodies that can be suitable for the treatment of cancer. The inventors produced new human antibodies directed against ROBO4 were by a phage display strategy and the antibody selection was performed by using HEK and HEK stably expressing ROBO4 (HEK-ROBO4) cell lines. As a first step, a batch of 6 different antibodies named D3, H3, H9, E11, H11 and G12 was tested for their binding properties. The antibodies were then tested for their ability to inhibit the attachment of tumor cells to osteoblastic cells in monolayers. Finally the inventors showed that the anti-ROBO4 antibodies E11 and G12 inhibits significantly the formation of the tumor spheroid. The present invention thus relates to anti-ROBO4 human monoclonal antibodies and uses thereof for the treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein are compositions and methods for preventing or attenuating the development of fibrosis and scarring, or for treating fibrosis and scarring that have resulted from implantation trauma, implantation and maintenance of a foreign body in the inner ear, such as a cochlear or vestibular implant, or from damage resulting from other injury to the inner ear, such as, for example, from electrical stimulation from an implant electrode.

IPC Classes  ?

• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61F 2/18 - Internal ear or nose parts, e.g. ear-drums

Abstract

A stimulation system designed to be implanted in a person and including several distributed elements connected by a wire bus comprising an energy wire, a data wire and a reference wire.

IPC Classes  ?

• A61N 1/372 - Arrangements in connection with the implantation of stimulators
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The invention relates to a method for recovering uranium from seawater, which uses complexation of uranium and filtration on a membrane made of an inorganic material and which comprises at least the steps of: a) complexing the uranium present in the seawater with at least one water-soluble organic polymer, comprising one or more groups complexing the uranium at the pH of the seawater, the organic polymer being retained by the membrane in the uncomplexed state and in the complexed state; b) passing the water obtained at the end of a) through the membrane, whereby, on either side of the membrane, a uranium-depleted permeate and a uranium-enriched retentate in the form of complexes are obtained; then c) collecting the retentate and dissociating the uranium complexes present in the retentate.

IPC Classes  ?

• C22B 3/20 - Treatment or purification of solutions, e.g. obtained by leaching
• B01D 61/02 - Reverse osmosisHyperfiltration
• B01D 61/14 - UltrafiltrationMicrofiltration
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C22B 3/22 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 60/02 - Obtaining thorium, uranium or other actinides
• C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
• C02F 1/66 - Treatment of water, waste water, or sewage by neutralisationTreatment of water, waste water, or sewage pH adjustment
• C02F 103/08 - Seawater, e.g. for desalination

Abstract

In general, the current disclosure relates to pre-queuosine1 (preQ1) affecting mammalian cellular function, including affecting proliferation of the mammalian cell. Aspects herein further show that preQ1 can affect tRNA abundance.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61P 35/00 - Antineoplastic agents
• C07D 487/04 - Ortho-condensed systems
• C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings

Abstract

Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a long follow-up by immunohistochemistry. They show that SPARC expression was detected in cancer cells (42.4%), cancer-associated fibroblasts (CATs) (88.1%). TAMs (77.1%), endothelial cells (75.2%) and TILs (9.8%). Recurrence-free survival (RFS) was significantly lower for patients with a positive expression of SPARC in CATs (SPARC+CATs) with a median follow-up of 5.4 years. SPARC expression in CATs was found to be an independent prognostic factor in multivariate analysis. Accordingly, the present invention relates to a method for predicting the survival time of a subject suffering from triple-negative breast cancer (TNBC) comprising determining the expression level of Secreted Protein Acidic and Rich in Cysteine (SPARC) in cancer-associated fibroblasts (CATs) in a biological sample obtained from the subject wherein said positive expression of SPARC in CATs (SPARC+CAFs) correlates with a short survival time of the subject.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a piezoelectric, epitaxially grown pseudosubstrate comprising a silicon wafer (100) having two parallel faces, and a thin layer of α-quartz (100) grown epitaxially on one of the faces of said wafer, said thin α-quartz layer (100) exhibiting a uniform crystallization with a mosaicity around the peak (100) of the quartz of between 6° and 1° and a thickness of between 100 nm and 1 μm. The present invention also relates to a process for fabricating such a pseudosubstrate, and to the use thereof for producing piezoelectric membranes.

IPC Classes  ?

• C30B 29/18 - Quartz
• C30B 1/02 - Single-crystal growth directly from the solid state by thermal treatment, e.g. strain annealing
• H03H 3/02 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks for the manufacture of piezoelectric or electrostrictive resonators or networks
• H03H 9/19 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator consisting of quartz

Abstract

The invention relates to a metamaterial comprising at least two components, including a first component that comprises, and preferably consists of, a dielectric oxide of at least one of the elements chosen from among Al, Ti, Ca, Mg, Ta, Hf and Zr; and a second component that comprises, and preferably consists of, a transparent electron-conductive oxide, the oxide being an oxide of at least one element chosen from among Zn, Sn, Ni, Ga, In and Cd, the conductive and dielectric oxides being inert with respect to one another at a temperature of 1000°C and at a pressure of 0.1 MPa, the components being present in the metamaterial in the form of a plurality of layers of the two components or of a wall consisting of one of the components on which a layer of the other component is deposited, the thickness of each layer or wall being less than 300 nanometers and the maximum distance between the two closest walls or layers of the same component being less than 300 nanometers.

IPC Classes  ?

• C04B 41/00 - After-treatment of mortars, concrete, artificial stone or ceramicsTreatment of natural stone
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• C04B 41/52 - Multiple coating or impregnating
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• H01L 31/0224 - Electrodes
• H01L 31/0392 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their crystalline structure or particular orientation of the crystalline planes including thin films deposited on metallic or insulating substrates
• H02S 10/30 - Thermophotovoltaic systems
• C23C 16/40 - Oxides
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C04B 111/00 - Function, property or use of the mortars, concrete or artificial stone
• C04B 111/92 - Electrically insulating materials
• C04B 111/94 - Electrically conducting materials

Abstract

A method for extracting at least one lanthanide element, preferably selected from lanthanum (La), praseodymium (Pr), neodymium (Nd), europium (Eu), dysprosium (Dy), and ytterbium (Yb), from a solid material including the lanthanide element, one or more waste elements such as iron (Fe), and/or one or more other lanthanide elements. The method implements a composition including water, at least one organic aprotic solvent, and at least one charged hydrotrope. Also, the use of the composition for recycling lanthanide elements, and more particularly WEEE, and for the decontamination of effluents.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 3/44 - Treatment or purification of solutions, e.g. obtained by leaching by chemical processes
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof

Abstract

The invention relates to a measurement device for measuring weak magnetic fields, such as fields in the sub-picotesla range (e.g. lower than a few nanotesla). The measurement device comprises ultrasensitive magnetic sensors (or arrays of ultrasensitive magnetic sensors) coupled to low-noise processing circuitry. The processing circuitry comprises a two-stage design including low-noise amplifiers and analog filters. The invention is suitable for magnetocardiovascular (MCV) applications thanks to its ability to measure very small magnetic fields with good accuracy and very little noise.

IPC Classes  ?

• A61B 5/243 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetocardiographic [MCG] signals
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01N 27/82 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables for investigating the presence of flaws

Abstract

The invention relates to novel compounds, referred to as pro-ligands or inactivated ligands, of formula (I). The invention also relates to conjugates comprising such pro-ligands, said conjugates corresponding to formula (II). The invention further relates to said conjugates (II) for use as a drug.

IPC Classes  ?

• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
• C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings

Abstract

A compound of formula I: A compound of formula I: A compound of formula I: wherein A is NH or CH2; G1 is a linear or a cyclic alkyl; Y1 is CH or N; Y2 is O, N or CH, W is O, N or CH; Z is NH or O; X1 and X2 and R, and R1 to R8 are functional groups. Also, a method of treating a viral infection or pathology linked to a viral infection in which an effective amount of the compound is administered to a patient in need thereof.

IPC Classes  ?

• C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• C07C 327/42 - Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
• C07C 335/16 - Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
• C07D 207/273 - 2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
• C07D 211/56 - Nitrogen atoms
• C07D 295/30 - Nitrogen atoms non-acylated
• C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

1163626163632344 independently represent a hydrogen atom or a halogen atom. It further relates to such a compound for its use as a medicament, and in particular for its use in treating and/or prevention of cancer, in particular cancer exhibiting recruitment of MDM2 to chromatin, more particularly selected from the group consisting of bone cancer, brain cancer, ovary cancer, breast cancer, lung cancer, colorectal cancer, osteosarcoma, skin cancer, blood cancer, including acute myeloid leukemia, pancreatic cancer, prostate cancer and liposarcoma and even more particularly selected from the group consisting of skin cancer, blood cancer, for example but not limited to acute myeloid leukemia, melanoma and liposarcoma.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 471/14 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Abstract

The inventors generated a new anti-Cath-D antibody (F1M1) which is able to reduce tumor growth without apparent toxicity in strongly immune-infiltrated Cath-D-secreting basal-like TNBC cell lines. F1M1 antibody prevented the recruitment of immunosuppressive M2- polarized tumor-associated macrophages (TAMs), and induced natural killer cell activation in tumors, F1M1 also enhanced the activation of anti -tumor M1 -polarized TAMs, the recruitment and maturation of conventional cDC1 dendritic cells in tumors to promote antigen presentation, and reduced the expression of exhaustion markers on CD4+and CD8+T cells in tumors and draining lymph nodes. Interestingly, the antibody F1M1 exhibit also a better affinity to Cath-D than the antibody F1 previously generated by the inventors. The inventors also generated a novel Fc-optimized F1M 1-Fc+human antibody that promotes ADCC induction on both cancer cells and CAF, improves antitumor potency, and triggers NK cell recruitment, activation and cytotoxic activity in tumors. F1M1-Fc+F1M1-Fc+inhibited growth of MDA-MB-231 and SUM159 TNBC cell xenografts, and of two TNBC-PDX (one resistant to neoadjuvant chemotherapy) without apparent toxicity. Moreover, this F1M1-Fc+ improves paclitaxel and enzalutamide therapeutic efficacy in combination. Thus, the present invention relates to anti- cathepsin-D antibodies and their use in the treatment of cancers, particularly of triple negative breast cancer.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Abstract

PIM2 kinase deregulation has been reported in several cancers. In particular, PIM2 is considered in multiple myeloma as part of the oncogenic process and several PIM kinase inhibitors have been developed showing encouraging results in preclinical studies and clinical trials. Now the inventors have developed an antisense RNA strategy based on a splice-switching oligonucleotide (SSO) so as to induce efficient knockdown of PIM2 expression. This SSO-mediated knockdown is a powerful approach to for cancer treatments. Accordingly, the present invention relates to the use of splice switching oligonucleotides for exon skipping-mediated knockdown of PIM2.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

An in vitro method is disclosed for characterizing a tumour, based on the quantitative analysis of modified and unmodified nucleosides from total cellular RNA, from extracellular RNA and/or from isolated nucleosides, extracted from a biological sample. More particularly, the invention relates to a method for predicting the grade of a glial tumour. More particularly, the invention also relates to a method for detecting a tumour. The present invention therefore lies in the fields of cancerology and molecular biology, more particularly applied to medical diagnosis.

IPC Classes  ?

• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• G01N 30/02 - Column chromatography
• G01N 30/72 - Mass spectrometers
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06N 3/09 - Supervised learning
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

An optical slide intended to receive a biological sample for the purposes of total internal reflection microscopy. Such an optical slide includes a glass base substrate and a stack of thin layers of alternating dielectric materials which is arranged on the substrate, the free layer of the stack being biocompatible. The stack has index and layer thickness characteristics for supporting the surface waves at the interface between the free layer and the sample, such that the imaging sensitivity and resolution of total internal reflection microscopy are improved.

IPC Classes  ?

• G02B 21/16 - Microscopes adapted for ultraviolet illumination
• G02B 5/26 - Reflecting filters
• G02B 21/08 - Condensers
• G02B 21/34 - Microscope slides, e.g. mounting specimens on microscope slides
• G02B 27/56 - Optics using evanescent waves, i.e. inhomogeneous waves

Abstract

The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

IPC Classes  ?

• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 215/38 - Nitrogen atoms
• C07D 215/42 - Nitrogen atoms attached in position 4
• C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A current switcher including: a positive supply bus and a negative supply bus; a floating-output current amplifier configured to make flow, as an output, an intermediate current dependent on a flowing setpoint current implied as an input; at least one anodic reference dipole connected between the positive supply bus and the floating-output current amplifier; at least one cathodic reference dipole connected between the floating-output current amplifier and the negative supply bus; and at least two stimulation bridges, each stimulation bridge including an anodic current source and a cathodic current source each configured to copy the intermediate current.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Method for extracting oleacein. The present invention relates to a method for treating co-products formed during olive oil production. The present invention also relates to a method for extracting active substances of cosmetic, therapeutic and/or nutritional interest.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• B01D 61/02 - Reverse osmosisHyperfiltration
• B01D 61/14 - UltrafiltrationMicrofiltration
• B01D 61/58 - Multistep processes
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• A61K 8/37 - Esters of carboxylic acids
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 19/00 - Preparations for care of the skin
• C02F 9/00 - Multistage treatment of water, waste water or sewage
• B01D 71/02 - Inorganic material
• C02F 1/38 - Treatment of water, waste water, or sewage by centrifugal separation
• C02F 1/66 - Treatment of water, waste water, or sewage by neutralisationTreatment of water, waste water, or sewage pH adjustment
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used

Abstract

The present invention relates to as powder composition comprising a specific degradable A and B block copolymer, at least one lubricant, and at least one haemostatic agent. The powder composition according to the invention is particularly useful in a method of preventing and/or treating haemorrhage preferably uterine haemorrhage. The invention also relates to a kit comprising (i) the powder composition of the invention, and (ii) means for inserting said powder composition into a body cavity, preferably into the uterine cavity.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

A neural stimulation device configured to apply neural activations including at least two interleaved sequences of current pulses, and a neurostimulation method. The device includes at least one neural electrode including at least two electrical contacts and intended to be implanted on at least one nerve; a current pulse generator connected to the at least one neural electrode via a current distributor; a storage element configured to contain a library of sequences, each sequence including a time series of current pulses associated with a configuration of electrical contacts; and a sequencer configured to apply neural activation to the at least one neural electrode, the neural activation including at least two interleaved sequences.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

The present disclosure relates to an Interleukin-6 (IL-6) signaling inhibitor selected from an IL-6 inhibitor, an IL-6 receptor inhibitor, an IL-6/IL-6 receptor complex inhibitor, a gp130 inhibitor and a STAT3 inhibitor or a pharmaceutical composition comprising such an IL-6 signaling inhibitor. for use in a method for treating and/or preventing cancer in a subject in need thereof. wherein the subject has been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin. The inventors have observed that cancers exhibiting recruitment of MDM2 to chromatin have been shown to secrete IL-6 that in turn acts on myoblast cells to activate serine synthesis. Following these surprising and unexpected observations. the inventors set up methods of treatment that are able to induce cancer cells death in subjects that have been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to an optoelectronic component (1) that is insensitive to dislocations, comprising: The invention relates to an optoelectronic component (1) that is insensitive to dislocations, comprising: a semiconductor heterostructure (2) able to emit laser radiation, said semiconductor heterostructure being formed from first semiconductors comprising a cascade of gain-providing active regions (21) in which the inter-band radiative transition is of type II, and The invention relates to an optoelectronic component (1) that is insensitive to dislocations, comprising: a semiconductor heterostructure (2) able to emit laser radiation, said semiconductor heterostructure being formed from first semiconductors comprising a cascade of gain-providing active regions (21) in which the inter-band radiative transition is of type II, and a carrier structure (30) comprising a non-native substrate (3) different from the first semiconductors, said semiconductor heterostructure (2) being formed by epitaxial growth on the carrier structure (30), The invention relates to an optoelectronic component (1) that is insensitive to dislocations, comprising: a semiconductor heterostructure (2) able to emit laser radiation, said semiconductor heterostructure being formed from first semiconductors comprising a cascade of gain-providing active regions (21) in which the inter-band radiative transition is of type II, and a carrier structure (30) comprising a non-native substrate (3) different from the first semiconductors, said semiconductor heterostructure (2) being formed by epitaxial growth on the carrier structure (30), wherein the active regions have a dislocation density higher than 107 .cm−2.

IPC Classes  ?

• H01S 5/343 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser
• H01S 5/02 - Structural details or components not essential to laser action
• H01S 5/34 - Structure or shape of the active regionMaterials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers

Abstract

A measuring device for measuring deformation, suitable for being placed in a borehole, comprises: a hollow elastic shell having a diameter compatible with the borehole into which it is inserted; a pressurization system for pressurizing the hollow elastic shell; and uniaxial sensors for measuring the elongation of the hollow elastic shell in at least six different directions.

IPC Classes  ?

• E21B 47/08 - Measuring diameters or related dimensions at the borehole
• E21B 49/00 - Testing the nature of borehole wallsFormation testingMethods or apparatus for obtaining samples of soil or well fluids, specially adapted to earth drilling or wells

Abstract

The invention relates to an immune cell comprising at least one Fc receptor on its surface, characterised in that a hybrid molecule is grafted onto the Fc receptor, said hybrid molecule comprising at least one antibody Fc fragment covalently bound to at least one fibrin-derived peptide comprising one or more citrullyl residue(s). The present invention also relates to the uses of such a grafted cell, as well as its method of production.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/735 - Fc receptors
• C07K 14/75 - Fibrinogen
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/0786 - MonocytesMacrophages

Abstract

The present invention concerns a compound of formula (I): The present invention concerns a compound of formula (I): The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 213/643 - 2-PhenoxypyridinesDerivatives thereof
• C07F 5/02 - Boron compounds

Abstract

A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(═O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

IPC Classes  ?

• C07D 215/38 - Nitrogen atoms
• A61P 31/14 - Antivirals for RNA viruses
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Provided herein are oligourea foldamers comprising the sequence of Ac-LUEULUKUPULUEULUKUAU2 2 (SEQ ID NO: 1) or Ac-LUEULUKUAULUEULUKUAU22 (SEQ ID NO: 2), and permeable membranes comprising thereof. Also provided herein is a method of purifying water using the permeable membranes.

IPC Classes  ?

• C08L 75/02 - Polyureas
• B01D 71/54 - PolyureasPolyurethanes
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

The present invention relates to novel conjugates having a general formula (I) as defined in claim 1. The conjugates of the invention comprise: 1/ at least one mannose 6-phosphate (M6P) analogue, the M6P analogue targeting both the cation-independent mannose 6-phosphate receptor (CI-MPR) and bone tissue; and 2/ a product of interest Y. The invention also relates to the method for preparing the conjugates and to the therapeutic or diagnostic medical use thereof. The conjugates of formula (I) of the invention are particularly beneficial for use as a medicament, in particular in the treatment of bone diseases and/or diseases affecting both bone tissue and soft tissue.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a hybrid molecule comprising a fibrin-derived citrullinated peptide and an antibody or antibody fragment which binds to CD38 and/or CD138, the uses of such a hybrid molecule and its method of production.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/745 - Blood coagulation or fibrinolysis factors

Abstract

A method for analysing a noisy sound signal for the recognition of at least one group of control keywords and of a speaker of the analysed noisy sound signal, the noisy sound signal being recorded by a microphone and the method including: supervised training of an artificial neural network using a training database in order to obtain a trained artificial neural network capable of providing, based on a sound signature obtained from a noisy sound signal, a prediction of the speaker and at least one prediction of a group of control keywords, the training database including a plurality of sound signatures, each associated with a speaker and with at least one group of control keywords; calculating a sound signature of the analysed noisy sound signal; using the trained artificial neural network on the calculated sound signature in order to obtain a prediction of the speaker and at least one prediction of a group of control keywords.

IPC Classes  ?

• G10L 25/84 - Detection of presence or absence of voice signals for discriminating voice from noise
• G10L 15/06 - Creation of reference templatesTraining of speech recognition systems, e.g. adaptation to the characteristics of the speaker's voice

Abstract

The present invention relates to the field of therapeutic treatment, particularly of cell therapy based on CD16+ cells and NK (Natural Killer) cells. In particular, the invention relates to a pharmaceutical composition comprising a CD16+ cell, a NK cell or a NK cell precursor, in combination with a recombinant polypeptide comprising a modified Fc region, in particular a modified CH2 domain. More particularly, the invention relates to a composition comprising a CD16+ cell and/or a NK cell, in combination with a recombinant polypeptide capable of binding to the FcγRIII (CD16) surface protein, wherein the recombinant polypeptide is non-covalently bound to the FcγRIII (CD16) surface protein expressed by the CD16+ cell, and wherein said recombinant polypeptide comprises: (i) a modified CH2 domain of a wild-type human IgG1, bound, optionally through a linker, to (ii) a ligand binding domain, wherein the ligand binding domain comprises a sequence capable of binding to a target ligand; wherein the modified CH2 domain is characterized by comprising mutations S239D and I332E with respect to the CH2 domain of a wild-type human IgG1, and wherein said CH2 domain of a wild-type human IgG1 is represented by SEQ ID NO 1, and comprises sequence positions 231-340, according to the EU numbering.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

MMinθ1inθ2θθ1θ2θ2θinin θ1θ1θinin θ22.

IPC Classes  ?

• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements
• G01N 21/64 - FluorescencePhosphorescence
• G02B 5/26 - Reflecting filters
• G02B 21/34 - Microscope slides, e.g. mounting specimens on microscope slides
• G02B 27/56 - Optics using evanescent waves, i.e. inhomogeneous waves

Abstract

The invention relates to a readout circuit comprising a readout amplifier for amplifying and latching a read data signal, via a bit line, in a memory cell (having a variable resistance) of a resistive memory. The readout amplifier comprises: two branches, each including two transistors mounted to form a logic inverter; a capacitor connecting the output of the logic inverter of the first branch with the input of the logic inverter of the second branch; two reference resistors and at least five switches. The variable resistor and the two reference resistors are connected to the input electrode of one of the four transistors, reducing power consumption and improving sensing speed and margins. Multi-phase operation allows readout with high sensing margins and fast sensing phases. The capacitor allows the effects of mismatches on the structure to be cancelled out.

IPC Classes  ?

• G11C 7/06 - Sense amplifiersAssociated circuits
• G11C 13/00 - Digital stores characterised by the use of storage elements not covered by groups , , or

Abstract

The present invention relates to a microfluidic chip capable of attracting and trapping a specific biological element, said chip comprising: a reservoir (1) consisting of a matrix comprising a chemoattractant compound capable of attracting the biological element, and at least one array of microchannels (2) arranged between the reservoir (1) and the external medium (3) of the chip and enabling the chemoattractant compound to pass towards said medium and the biological element present in said medium to pass towards the reservoir (1), characterized in that each microchannel is in the form of a harpoon comprising at least two arrows spaced apart longitudinally and directed towards the reservoir, in which each arrow comprises two branches each having a free end forming an acute angle of between 10° and 80°, and in which each arrow comprises two openings (7) communicating with a longitudinal part of the microchannel and having a width of between 5 μm and 30 μm.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present application relates to novel bifunctional PROTAC-type compounds simultaneously binding the target protein PXR and E3-ubiquitin ligase, to a method for preparing same, and to uses thereof for treating cancers overexpressing PXR.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents
• C07D 235/14 - Radicals substituted by nitrogen atoms

Abstract

The present invention relates to a carbonaceous polymeric material also referred to as porous carbonaceous material complexed with at least one metal ion, preferably a metal cation, a composition comprising a protein immobilized on said material, and methods of preparing the same. The invention further relates to the use of the composition comprising an immobilized protein in particular in heterogeneous biocatalysis applications.

IPC Classes  ?

• C08L 73/00 - Compositions of macromolecular compounds obtained by reactions forming a linkage containing oxygen or oxygen and carbon in the main chain, not provided for in groups Compositions of derivatives of such polymers
• C12N 11/089 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

The present invention relates to a carbon-based polymer material also referred to as a porous carbon-based material complexed with optionally at least one metal ion, preferably a metal cation, and a composition comprising a protein immobilized on said material and methods for preparing same. The invention further relates to the use of the composition comprising an immobilized protein in heterogeneous biocatalysis applications in particular.

IPC Classes  ?

• C12N 11/089 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• C08L 73/00 - Compositions of macromolecular compounds obtained by reactions forming a linkage containing oxygen or oxygen and carbon in the main chain, not provided for in groups Compositions of derivatives of such polymers

Abstract

The present invention relates to new amphiphilic perfluorinated compounds and their use as a detergent for extracting membrane-proteins or synthesizing membrane-proteins in acellular system. It also relates to a method for extracting a membrane-protein from a biological sample using such compounds.

IPC Classes  ?

• C11D 1/00 - Detergent compositions based essentially on surface-active compoundsUse of these compounds as a detergent
• C07C 317/28 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• C07H 15/06 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical being a hydroxyalkyl group esterified by a fatty acid
• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• C07K 14/245 - Escherichia (G)

Abstract

The invention relates to a timer device for activating a spacecraft passivation system. The timer device (2) is made up of a control device (4) coupled to a dosimeter (6). The dosimeter is capable of characterizing a dose of radiation to which a spacecraft is exposed during its mission, so that the control device (4) can know the dose of radiation absorbed by said dosimeter (6). The control device (4) is capable of activating a system for passivating a spacecraft when the dose of radiation received by said dosimeter (6) exceeds a reference value, corresponding to a predetermined time of flight on a predetermined orbit.

IPC Classes  ?

• B64G 1/66 - Arrangements or adaptations of apparatus or instruments, not otherwise provided for
• B64G 1/42 - Arrangements or adaptations of power supply systems

Abstract

The present invention relates to compounds derived from 7-azaindole useful as inhibitors of AXL kinases for the treatment of viral infections. The present invention also relates to their method of preparation. Specifically, the invention relates to compounds of formula (I): for use in the prevention and/or treatment of viral infections.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

OO>-2-methoxyethyl-modified FXYD2-LASO (FXYD2- LASO-Gapmer) and injected them intravenously, a less invasive administration route. The intravenous administration of FXYD2 optimized antisense oligonucleotide (LASO) with MOE allows a long-time effect on the pain compared to an intrathecal administration. Inventors have demonstrated this long-lasting effect on neuropathic pain in the Spinal Nerve Ligation (SNL) rat model and inflammatory pain in the Complete Freund's Adjuvant (CFA)- induced rat model. Accordingly, the invention relates to antisense oligonucleotide targeting FXYD2 for use in the treatment of pain, wherein said antisense oligonucleotide is administered intravenously.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The inventors previously demonstrated that mitochondrial VDAC1 directly induces Schwann cell demyelination via MAPK and c-jun activation after sciatic nerve injury and diabetic neuropathy and CMT1A. They found that reduction of mitochondrial calcium release by VDAC1 blocking strongly reduces the number of demyelinating Schwann cell in vivo and improve nerve conduction and neuromuscular activity in diabetic, Guillain-Barre syndrome and Charcot-Marie Tooth disease models. Herein, the inventors precisely map the binding region of the N-terminal HK-1 helix through an ala scan completed by a deletion study. Furthermore, they optimized the HK-derived peptide through stabilization of the helix by replacement of non-essential amino acids by the a-aminoisobutyric acid (Aib) known as a helix inducer. Additionally, they described an in-house cellular screening assay based on the ability of MJ to detach HK from VDAC that allows to determine the peptide potency. Overall, their data confirm that N-terminal HK derived peptides acting on VDAC are promising tools for the study of the demyelination process. Thus, the present invention refers to optimized HK-derived peptide and its use for treating peripheral demyelinating disease, myocardium diseases10 11, cancer12,13-15, diabetes14 14-16, lupus-like diseases17, non-alcoholic fatty liver disease24,25, chemoinduced neuropathy9 Alzheimer disease18 19, Parkinson disease20, Huntington disease21, ALS22,23 and more generally all neurodegenerative diseases linked to a protein aggregation28.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed is a light conversion method in which light having a wavelength of 300 nm to 580 nm produced by a light source (1) converting electrical energy into light is subjected to a luminescent material (2) having graphitic-core quantum carbon dots dispersed in a matrix, said quantum carbon dots producing, in response to this illumination, red light having a wavelength of 625 nm to 740 nm.

IPC Classes  ?

• H01L 33/50 - Wavelength conversion elements
• H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof

Abstract

The present invention relates to a crosslinkable polymer composition comprising at least one calcium phosphate, at least one biocompatible and biodegradable organic polymer or one of its precursors, and Zn-ZnO core-shell particles, to a biomaterial obtainable by photopolymerization of such a crosslinkable polymer composition, to a process for preparing such a composition and such a biomaterial, and to the use of such a biomaterial for various applications in the field of health.

IPC Classes  ?

• A61K 6/62 - Photochemical radical initiators
• A61C 8/02 - Means for transfixation of natural teeth
• A61F 2/28 - Bones
• A61K 6/824 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising transition metal oxides
• A61K 6/887 - Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
• C01G 9/00 - Compounds of zinc
• C01G 9/02 - OxidesHydroxides
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials

Abstract

The present invention belongs to the field of water purification and decontamination. The present invention relates to new versatile family of trianglamine based compound and their uses thereof as is or in the manufacture of membranes and gels useful to purify and decontaminate water.

IPC Classes  ?

• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• C07D 259/00 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms

Abstract

The invention relates to a method for extracting at least one rare earth from an aqueous solution Al of an organic acid or of a mixture of organic acids comprising, in addition to one or more rare earths, one or more transition metals, which method comprises at least one step of bringing the aqueous solution Al into contact with a water-immiscible organic solution comprising, as an extractant, the diglycolamide of formula (I): dissolved in an organic diluent, followed by separating the aqueous solution Al from the organic solution, wherein the method is characterised in that the aqueous solution Al further comprises a salting-out agent. It also relates to a method for recovering, together or separately, the thus extracted rare earths.

IPC Classes  ?

• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 3/32 - Carboxylic acids
• C22B 59/00 - Obtaining rare earth metals
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof

Abstract

in vitro in vivo in vivo use of the anti-SLC1A4 monoclonal antibodies disclosed therein for diagnosis purpose.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

in vitroin vivoin vivo methods of specifically detecting or/and measuring the level of ASCT1, and to the use of said polypeptides in diagnosis and therapy.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus

Abstract

The present invention concerns a method for the molecular detection of an infectious agent based on isothermal amplification by recombinase polymerase amplification (RPA) combined with a Magnetic Field-Enhanced Agglutination (MFEA) readout.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.

IPC Classes  ?

• C07D 215/38 - Nitrogen atoms

Abstract

The present invention relates to a finished leather having at least one ennobled property provided by at least one silylated treatment agent, and to the methods for preparing such a finished leather, comprising the use of a silylated compound during the tanning step and/or during an ennoblement step performed after tanning.

IPC Classes  ?

• C14C 3/08 - Chemical tanning by organic agents
• C14C 3/02 - Chemical tanning
• C14C 3/28 - Multi-step processes
• C14C 9/00 - Impregnating leather for preserving, waterproofing, making resistant to heat or similar purposes
• C14C 11/00 - Surface finishing of leather
• C14C 3/22 - Chemical tanning by organic agents using polymerisation products

Abstract

Respiratory muscle contractile inactivity during mechanical ventilation (MV) induces diaphragm muscle weakness, a condition referred to as ventilator-induced diaphragm dysfunction (VIDD). Among the different hypothesis to explain VIDD, one involves the remodeling of the sarcoplasmic reticulum (SR) calcium release channel/ryanodine receptors (RyR1) in the diaphragm as a proximal mechanism of VIDD. The inventors have developed novel derivatives which prevent with a high efficiency VIDD both in a murine and porcine model of VIDD. This effect is associated with a normalization of RyR function. The present invention thus relates to novel compounds and their use in the treatment of diseases associated with Ryanodine Receptor (RyR) dysfunction.

IPC Classes  ?

• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses
• C07C 1/00 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon

Abstract

An imaging method and device configured to provide an image of an implant previously stored in a database, taking into account an arrangement of an implant implanted in a body is disclosed. To this end, a sensor such as a proximity sensor disposed outside the body is configured to detect a portion of the implant in order to determine data relating to the positioning of same within the body.

IPC Classes  ?

• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• G06T 17/00 - 3D modelling for computer graphics
• G06T 19/00 - Manipulating 3D models or images for computer graphics
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention relates to a method of polymerizing at least one fluorinated monomer comprising an ethylene bond, the method comprising putting in contact the at least one fluorinated monomer with a polymerization initiator and a chain transfer agent, the chain transfer agent being a polysulfide compound, preferably a disulfide compound. The invention also relates to a telechelic fluoride-based polymer obtained with said method.

IPC Classes  ?

• C08F 14/22 - Vinylidene fluoride

Abstract

The present invention relates to the diagnostics of pancreatic cancer. The inventors engineered a novel biomarker discovery approach, tailored for PDAC, which is all-patient inclusive, termed PanEXPEL. This approach offers access to PDAC clinical material before any treatment is applied. The method benefits from clinical biopsy, yet does not interfere with that diagnostic procedure. It can be integrated seamlessly into clinical routine, and is compatible with any type of OMICS profiling. PanEXPEL relies on the interstitial tissue fluid released from the lesion during diagnostic biopsy by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). This is the first technique that allows both clinicians and researchers to analyze identical material in the field of proteomics biomarker research. Here, they demonstrate the potential of PanEXPEL methodology by identifying a PDAC early detection signature through proteomics and subsequent statistical learning. Thus, the present invention relates to a method for diagnosing a pancreatic cancer in a subject in need thereof comprising determining in a sample obtained from the subject the expression levels of at least one biomarker selected from the group consisting of AGR2, ANXA2, ANXA3, ANXA4, CECAM6, CYP2S1, DMBT1, KRT7, KRT8, KRT17, KRT18, KRT19, MAL2, MYH14, 0LFM4, PIGR, SERPINB5, SERPINH1, and TIMP1.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention relates to products comprising at least one inhibitor of SERCA2 (Sarco/Endoplasmic Reticulum Ca2+−AT-Pase 2) according to the invention, and at least one activator of STING, as combination products for a simultaneous, separate or sequential use in the treatment and/or prevention of a cancer.

IPC Classes  ?

• A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention concerns a neuromorphic circuit (10) implementing an oscillatory neural network, the neuromorphic circuit (10) comprising : - neuron units (12), each neuron unit (12) being an analog oscillator adapted to convert an incoming analog signal having a specific waveform on an analog input (12I) of the neuron unit (12) into a digital output signal, and - synapse units (14), each synapse unit (14) being adapted to multiply a digital output from a neuron unit (12) with a respective synaptic weight to output a weighted signal sent to the analog input (12I) of a neuron unit (12).

IPC Classes  ?

• G06N 3/065 - Analogue means

Abstract

Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. Here, the inventors studied the effects of intra-articular anti-GD3 monoclonal antibody injection. The present invention relates to a method for treating osteoarthritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a GD3 inhibitor.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

48481436141414142214141414141414144)alkoxy group. The present invention further related to a pharmaceutical composition comprising it and to its use in the prevention and/or the treatment of pain.

IPC Classes  ?

• C07D 215/40 - Nitrogen atoms attached in position 8
• C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
• C07D 237/30 - Phthalazines
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine

Abstract

Methods for screening a subject for a cancer are provided. In particular, the methods include i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are thoroughly modified by the resident gut microbiota. Bile acids act as versatile signaling molecules with a variety In of endocrine functions and are linked to several diseases. In particular, serum and urinary bile salts represent biomarkers for early diagnostics of liver dysfunction, yet their current detection methods are impractical and hard to scale. Here the inventors engineered engineered synthetic bile salt receptors using VtrA as sensing domains connected to E. coli CadC system which activates transcription upon dimerization. The performance of the system was assayed for various selection of promoters and they can show that fine tunable response that may be reached by changing expression levels of the bile salt receptor. By performing multiple rounds of directed evolution of the VtrA sensor the inventors obtained a collection of variants with a lower limit of detection and a higher sensitivity. Finally, they show that their bactosensor can detect pathological bile-salt concentrations in samples from patients with liver dysfunction. The present invention thus relates to bile salts bactosensor and use thereof for diagnostic and therapeutic purposes.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention primarily relates to a biobased polyurethane resin composition, characterised in that it is obtained by mixing a volume V1 of polyisocyanate phase and a volume V2 of polyol phase, and in that: - either the polyisocyanate phase includes at least two polyisocyanates, at least one of which is an isocyanate-terminated prepolymer that comprises at least 70% biobased carbons and the other comprises at least 60% biobased carbons, and the polyol phase includes at least one polyol that comprises at least 80% biobased carbons, - or the polyol phase includes at least two polyols that each comprise at least 80% biobased carbons, and the polyisocyanate phase includes at least one isocyanate-terminated prepolymer that comprises at least 70% biobased carbons. Preferentially, the number of isocyanate functions in the polyisocyanate phase is equal to the number of alcohol functions in the polyol phase. The invention also relates to a method for manufacturing such a composition, which method advantageously involves evaluating the equivalent reactive volumes of each compound. The invention lastly relates to a printed support at least partially covered with a dome of resin, which dome of resin is produced from said polyurethane resin composition.

IPC Classes  ?

• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/36 - Hydroxylated esters of higher fatty acids
• C08G 18/48 - Polyethers
• C08G 18/66 - Compounds of groups , , or
• C08G 18/72 - Polyisocyanates or polyisothiocyanates
• C08G 18/79 - Nitrogen characterised by the polyisocyanates used, these having groups formed by oligomerisation of isocyanates or isothiocyanates
• C09D 175/04 - Polyurethanes
• C09D 175/08 - Polyurethanes from polyethers
• C08L 75/04 - Polyurethanes

Abstract

The invention relates to the use of a lipophilic derivative of an aminopolycarboxylic acid as an extractant to extract at least one rare earth from an acidic aqueous solution. Applications: production of rare earths from concentrates derived from urban ores and, in particular, from concentrates from waste electrical and electronic equipment such as used or discarded NdFeB permanent magnets; production of rare earths from concentrates derived from natural ores or from concentrates derived from residues of natural ores.

IPC Classes  ?

• C22B 59/00 - Obtaining rare earth metals
• C22B 3/28 - Amines
• C22B 3/32 - Carboxylic acids
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

A method for recognizing a pattern in an image including a training phase of an oscillatory neuron network, the oscillatory neuron network being adapted to output a pattern when an image is inputted, the oscillatory neuron network being implemented by a circuitry comprising oscillators linked by interconnections including at least one coupling resistance having a coupling resistance value, the oscillators being coupled by a sub-harmonic injection technique and coding the output by their relative phase difference, the coupling resistance values being learnt during the training phase by using Hebbian learning rules, and an operating phase wherein the trained oscillatory neuron network is used to recognize a pattern in an image, at least one of the training phase and the operating phase being computer-implemented.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding

Abstract

A novel method for synthesizing NCA compounds. Also, a new use of a peptide coupling agent. The method makes it possible to obtain NCA compounds from α-amino-acids, under mild and non-racemic reaction conditions, and in the absence of constraining reagents of use, such as phosgene, which may lead to the formation of undesirable by-products.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 263/06 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
• C07D 498/04 - Ortho-condensed systems

Abstract

The invention relates to a method (100) for assisting the determination of a dosage of antioxidants to be administered to a patient suffering from oxidative stress, said method (100) comprising at least one iteration of a prediction phase (108) comprising the following steps: - measurement (110), on a blood sample previously taken from said patient, of a level of at least the following input parameters: cholesterol level, zinc level, copper level, vitamin C level, vitamin E level, and selenium level; - estimation (130) of a dosage for at least one antioxidant to be administered to said patient, via a previously trained estimation model, executed by a calculation unit, said estimation model taking as input said at least one input parameter. The invention also relates to a device which implements such a method.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The present invention relates to a process for tanning hides using a tanning solution that comprises a silicon compound and is free from metals. The invention also relates to a method for preparing leather that includes a tanning process of this type. The invention also relates to tanned hides obtained by such a tanning process. The invention further relates to a process for detanning the hides obtained by means of the above tanning process.

IPC Classes  ?

• C14C 3/08 - Chemical tanning by organic agents

Abstract

A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The invention relates to a hybrid molecule comprising at least one antibody Fc portion covalently bound to at least one peptide binding to a self-reactive lymphocyte responsible for autoimmune dermatitis, the uses of such a hybrid molecule, and a method for producing same.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• A61P 17/00 - Drugs for dermatological disorders
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 9/50 - Proteinases

Abstract

The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPARβ/δ agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPARβ/δ agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPARβ/δ agonist to the subject.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

The invention relates to a hybrid molecule comprising at least one antibody Fc portion covalently bound to at least one peptide binding to a self-reactive lymphocyte involved in autoimmune vasculitis, to the uses of such a hybrid molecule, and to a method for producing same.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/08 - Oxidoreductases (1.), e.g. luciferase acting on hydrogen peroxide as acceptor (1.11)
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present invention relates to the treatment of cancer. Here, the inventors identified a subset of prostate cancer patients showing an up-regulation of the epigenetic enzymes SUV4-20H1 and SUV4-20H2, two methyltransferases responsible for the di- and tri- methylation of histone H4 at lysine 20 (H4K20me2/3). Consistent with this, the inventors demonstrate that the pharmacological inhibition of both SUV4-20H1 and SUV4-20H2 enzymes by the chemical compound A196 (14) leads to the complete loss of H4K20me2/3 states in prostate cancer cells. Although displaying epigenetic reprograming at genome-wide levels, cancer cells display any significant impairment in their survival or proliferation, thereby demonstrating that the inhibition of SUV4-20H1 and SUV4-20H2 is not toxic per se. Yet, the inventors showed that the pharmacological inhibition of SUV4-2H1 and SUV4-20H2 subtly affects DNA repair mechanisms and the levels of trapped topoisomerase II (TOPO2) complex in silent chromatin regions upon TOPO2 poisons. This creates in vitro as well as in vivo a lethal synergy between A196 and the TOPO2-poison etoposide in prostate cancer cells. Altogether, the results of the inventors showed that the simultaneous inhibition of SUV4-20H and TOPO2 enzymatic activity constitutes indeed a new therapeutic approach for the treatment of advanced or metastatic prostate cancers, which are particularly addicted to SUV4-20H2 and TOPO2 activities. Other cancers could also benefit of this drug combination, since the co-treatment of A196 and etoposide induces similar lethal synergy in other epithelial cancer cells such as breast cancer cell lines. Thus, the present invention relates to a combination of a SUV4-20H inhibitor and a TOPO2 inhibitor for use in the treatment of a cancer in a subject in need thereof.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the treatment of cancers linked to cancer-associated fibroblasts (CAF). In this study, the inventors have studied the LTBP2+ CAF subset that is responsible for desmoplastic reaction in CRC-LM. They have used gene invalidation experiments to better understand the potential function of these cells, and they have also developed a fully human antibody that enables targeting of LTBP2+ CAF and their depletion in vitro. These new insights identify for the first time a CAF entity within CRC liver metastases whose targeting may be become a valuable asset in the development of new anti-tumor agents. Thus, the present invention relates to antibodies having specificity to LTBP2 and uses thereof.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

A method for stripping U(VI) and an An(IV) from an organic solution including tri-n-butyl phosphate in an organic diluent, the solution containing U(VI) and the An(IV) present as U(VI) nitrate and An(IV) nitrate at concentrations such that the U(VI) nitrate concentration is higher than the An(IV) nitrate concentration, and the sum of the U(VI) nitrate and An(IV) nitrate concentrations is ≥55 g/L. The method includes contacting the organic solution and an aqueous solution of nitric and oxalic acids, the oxalic acid concentration in the aqueous solution and the O/A volume ratio selected so that the oxalic acid is deficient with respect to the stoichiometric conditions of a complete precipitation of U(VI) and actinide(IV), to obtain a precipitate containing the actinide(IV) in oxalate form and a fraction of the U(VI) in oxalate form with a U(VI)/actinide(IV) mass ratio of between 0.5 and 5; and separating the precipitate from the organic and aqueous solutions.

IPC Classes  ?

• G21F 9/12 - Processing by absorptionProcessing by adsorptionProcessing by ion-exchange

Abstract

In vitroin vivoin vivo.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/18 - Sulfonamides
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to an inhibitor of FXYD2 wherein said inhibitor reduces the expression and/or activity of FXYD2 in a subject in need thereof and targets at least the region comprising or consisting of the nucleotides 219-229 of SEQ ID NO: 3. Inventors have shown that targeting a region of FXYD2 can be used to inhibit and/or reduce the expression and/or activity of FXYD2. They have designed and synthesized an antisense oligonucleotide (SEQ ID NO: 4) targeting the rat and human FXYD2 gene. The have performed intrathecal injection of FXYD2 optimized ASO in two rat models of pain (neuropathic and inflammatory pain). They have shown that FXYD2 ASO efficiently reduces its expression in rat Dorsal root ganglion (DRG). The have demonstrated that FXYD2 ASO dramatically reduces neuropathic pain in the Spinal Nerve Ligation (SNL) rat model and analgesic effect of FXYD2 ASO on neuropathic pain is greater than that of Ziconotide, the current market leader. They also have shown that FXYD2 ASO dramatically reduces inflammatory pain in Complete Freund's Adjuvant (CFA)-induced rat model.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

Retinitis pigmentosa (RP) is an inherited retinal dystrophy that causes progressive vision loss. The second most common mutation causing autosomal dominant (ad) RP is the G56R mutation in NR2E3, a transcription factor essential for photoreceptor development. The G56R variant is exclusively responsible for all cases of NR2E3-associated adRP. Currently, there is no treatment for NR2E3-related, or other, adRP, but genome editing holds promise. In this study, the inventors developed a CRISPR/Cas strategy to specifically knockout the mutant G56R allele of NR2E3 and performed a proof-of-concept study in iPSC of an adRP patient. They demonstrate allele-specific knockout of the mutant G56R allele in the absence of off-target events. Furthermore, they validated this knockout strategy in an exogenous overexpression system. They showed for the first time that G56R iPSC, as well as G56R-CRISPR iPSC, can differentiate into NR2E3-expressing retinal organoids. Overall, they demonstrate that G56R allele-specific knockout by CRISPR/Cas could be a clinically relevant approach to treat NR2E3-associated adRP.Thus, the invention refers to a site-directed genetic engineering system for specifically editing an allele containing c.166G>A mutation in NR2E3 in the genome of an individual and its use for treating autosomal dominant retinitis pigmentosa.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 38/46 - Hydrolases (3)
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to the field of neuromuscular disorders (NMDs) and corresponding quantification methods. There indeed remains a strong need for novel drugs for the treatment and prevention of neuromuscular disorders. The inventors showed that the compounds according to the invention allow restoring locomotion and cellular related parameters: neuromuscular junctions structure, in particular by improving AChR clustering, and/or by increasing the co-localization of presynaptic nerve terminals and AChR microclusters, and/or by rescuing axonal outgrowth, in an individual with a neuromuscular disorder. In particular, the present invention relates to new compounds suitable for treating and/or preventing a neuromuscular disorder in an individual in need thereof. The present invention also relates to a method for automating the quantification of axons and/or neuromuscular junctions in a whole organism or in a biological sample and to a method for the identification of a compound able to prevent and/or treat a neuromuscular disorder in an individual in need thereof.

IPC Classes  ?

• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/18 - Sulfonamides
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/417 - Imidazole-alkylamines, e.g. histamine, phentolamine

Abstract

Inventors have used FXYD7 knock-out mouse line and DRG-specific conditional Knock-out mice to demonstrate that the constitutive or DRG-specific knock-out of the FXYD7 gene specifically alleviate mechanical chronic pain induced by peripheral inflammation, but not by peripheral nerve lesions. They have also showed that: i) FXYD2 and FXYD7 are expressed by distinct and complementary somatosensory neuron subtypes suggesting specific functions in the somatosensory system; ii) FXYD7 is largely dispensable for neuronal differentiation and survival; iii) in FXYD7-/- animals, FXYD7 expression was not affected in the DRG. Accordingly, the present invention relates to a method for treating a subject suffering from a chronic pain disorder comprising a step of administrating said subject with a therapeutically effective amount of an inhibitor of FXYD7.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Abstract

The present invention relates to the creation of an electromechanical microsystem in the form of a piezoelectric resonant membrane comprising a piezoelectric epitaxial pseudo-substrate based on an epitaxial α-quartz layer on a silicon wafer, as well as to a process for manufacturing such a microsystem.

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
• H10N 30/01 - Manufacture or treatment

Abstract

The invention provides a silica aerogel comprising one or more channels, each channel having a surface roughness of from about 0.1 to about 10 µm, an internal diameter in the range of from about 100 µm to about 2900 µm and a length of from about 5mm to about 200 mm.

IPC Classes  ?

• B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons

Abstract

The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an efficient amount of said high-Z element containing nanoparticles and of an efficient amount of a radionuclide containing therapeutic radiopharmaceutical, wherein the high-Z element containing nanoparticles contain an element with an atomic Z number higher than 40, preferably higher than 50, and wherein said nanoparticles have a mean hydrodynamic diameter of 20 nm or less, for example between 1 and 10 nm, preferably between 2 and 8 nm.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61K 103/30 - Rare earths

Abstract

The inventors have now succeeded in developing compounds of Formula (I), described below, having the advantage of inhibiting NAD kinases, in particular P. aeruginosa NADK (PaNADK) enzyme, Listeria monocytogenes (LmNADK) enzyme and/or human cytosolic NADK (HsNADK) enzyme. The present invention relates to benzamide adenine dinucleoside compounds which are useful as inhibitors of NAD kinases, to pharmaceutical composition comprising such compounds, and to uses of such compounds in the treatment or prevention of bacterial infections.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• C07H 19/167 - Purine radicals with ribosyl as the saccharide radical

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The present invention relates to a compound of the following formula (I): The present invention relates to a compound of the following formula (I): The present invention relates to a compound of the following formula (I): in particular for use in a method for preventing or treating a disease in an individual, more particularly for preventing or treating a disease is associated to progerin or to prelamin A.

IPC Classes  ?

• C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• C07C 271/02 - Carbamic acidsSalts of carbamic acids
• C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to a process and an installation wherein a ternary system comprising an aqueous acidic solution, an organic solvent not miscible with water and a thermosensitive hydrotropic agent is used to selectively extract tantalum and optionally niobium by cycling extraction between low- temperature single-phase and high temperature two phase regions in the ternary phase prism far from the critical point.

IPC Classes  ?

• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 34/24 - Obtaining niobium or tantalum
• B01J 38/50 - Liquid treating or treating in liquid phase, e.g. dissolved or suspended using organic liquids
• B01J 38/60 - Liquid treating or treating in liquid phase, e.g. dissolved or suspended using acids
• C01G 33/00 - Compounds of niobium
• C01G 35/00 - Compounds of tantalum

Abstract

A method of selecting T cells with improved anti-cancer activity, the method including: a) quantifying glucose transporter 1 (GLUT1) expression level at the cell surface of a population of T cells by using a GLUT1 ligand, b) selecting T cells having a low GLUT1 expression level, wherein the T cells having a low GLUT1 expression level have improved anti-cancer activity. Also, a population of T cells with improved anti-cancer activity for use in the treatment of cancer, to the use of a GLUT1 ligand for selecting T cells with improved anti-cancer activity, and to the use of GLUT1 as a biomarker of the anti-cancer therapeutic efficacy of T cells.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants